Vericel (VCEL) Preferred Stock Liabilities (2012 - 2013)
Vericel (VCEL) posted Preferred Stock Liabilities of $42.9 million for Q2 2013, little changed sequentially from $42.9 million in Q1 2013, and up 13.76% YoY from $37.7 million in Q2 2012.
Vericel (VCEL) Preferred Stock Liabilities (2012 - 2013) Analysis & Trends
Vericel has reported Preferred Stock Liabilities for 2 years, with the latest figure at $42.9 million in Q2 2013.
- Quarterly Preferred Stock Liabilities rose 13.76% year-over-year to $42.9 million in Q2 2013, while the trailing twelve-month figure through Jun 2013 was $42.9 million (up 13.76% YoY) and the FY2012 annual result came in at $41.6 million, changed N/A from the prior year.
- Preferred Stock Liabilities steadied at $42.9 million in Q2 2013 per VCEL's latest filing, from $42.9 million in the prior quarter.
- Over five years, Preferred Stock Liabilities peaked at $42.9 million in Q1 2013 and troughed at $37.7 million in Q2 2012.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Vericel | 2.26 Bn | 2.10 Bn | 56.40 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2013 | 42.88 Mn |
| Mar 31, 2013 | 42.88 Mn |
| Dec 31, 2012 | 41.61 Mn |
| Sep 30, 2012 | 40.36 Mn |
| Jun 30, 2012 | 1.45 Mn |